Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Significance of MRD negativity in Ph-negative ALL

Ivan Moiseev • 1 Sep 2020
EBMT 2020
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab CAR-T Inotuzumab ozogamicin

Ivan Moiseev, MD, PhD, First Saint Petersburg State Medical University, Saint Petersburg, Russia, explores factors predicting the outcome of allogeneic stem cell transplantation in patients with Philadelphia chromosome-negative (Ph-negative) acute lymphoblastic leukemia (ALL), with the main predictor being minimal residual disease (MRD) negativity. Dr. Moiseev outlines strategies to achieve MRD negative remission including treating with agents such as blinotuzumab, inotuzumab as well as CAR T-cell therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ivan Moiseev

GO-FLAG: bridge therapy to allo-SCT in R/R AML
0:53
GO-FLAG: bridge therapy to allo-SCT in R/R AML
Ivan Moiseev • 30 Aug 2020
Impact of post-transplant TKIs on long-term outcomes of allo-HSCT in ALL
1:27
Impact of post-transplant TKIs on long-term outcomes of allo-HSCT in ALL
Ivan Moiseev • 1 Sep 2020
Mutational profiles of MDS patients undergoing allo-HSCT
1:29
Mutational profiles of MDS patients undergoing allo-HSCT
Ivan Moiseev • 30 Aug 2020
Allo-HSCT in BCR-ABL-negative MPN pretreated with JAK inhibitors
1:06
Allo-HSCT in BCR-ABL-negative MPN pretreated with JAK inhibitors
Ivan Moiseev • 1 Sep 2020

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals